U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06849063) titled 'Assessment of the Prognosis of Pancreatic Cancer Patients Using 3D MRE' on Feb. 23.
Brief Summary: Pancreatic ductal adenocarcinoma (PDAC), representing 85-95% of pancreatic cancers, is a highly lethal malignancy with a dismal 5-year survival rate below 8%. Emerging evidence highlights the critical need for non-invasive imaging biomarkers to stratify prognosis and guide therapeutic strategies. Notably, the biomechanical properties of PDAC-associated extracellular matrix (ECM), characterized by extensive interstitial fibrosis, are intrinsically linked to tumorigenesis, progression, and metastatic dissemination. Three-dimensional magn...